Effects of medications on uterine contractions during cesarean delivery in diabetic patients
Official title: Effect of Ephedrine, Phenylepinephrine, and Norepinephrine on Myometrial Contractility in Pregnant People With Type II and Gestational Diabetes During Cesarean Section: An In-vitro Study
Run by Samuel Lunenfeld Research Institute, Mount Sinai Hospital · NCT06285396 · Data updated 2026-11-12
This study is testing how certain medications for low blood pressure during cesarean deliveries affect uterine contractions in women with Type II and gestational diabetes.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 19 Years to 45 Years |
| Sex | Women only |
| Enrollment | 96 (estimated) |
| Sponsor | Samuel Lunenfeld Research Institute, Mount Sinai Hospital Academic / other |
| Locations | 1 site (Toronto, Ontario) |
| Status | Recruiting |
| Started | March 18, 2024 |
| Main results expected | December 2026 |
| Study ends | December 2026 |
| Registry record updated | April 6, 2026 |
| Trial ID | NCT06285396 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include pregnant individuals aged 19-45 with Type II or gestational diabetes, scheduled for elective cesarean delivery under spinal anesthesia.
✕Probably not a fit
Patients who are in labor, require general anesthesia, or have had previous uterine surgeries may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates how medications used to treat low blood pressure during cesarean deliveries affect the contractility of uterine muscle tissue in patients with Type II and gestational diabetes. It focuses on the impact of vasopressors like ephedrine, phenylephrine, and norepinephrine on myometrial function, as inadequate contractions can lead to postpartum hemorrhage, particularly in diabetic women. The research aims to provide insights into the relationship between these medications and uterine health during a critical time for mothers undergoing elective cesarean sections.
Why it matters
Potential benefit: If successful, this study could lead to improved management of uterine contractility and reduced risk of postpartum hemorrhage in diabetic patients during cesarean deliveries.
How similar studies have gone: While the specific approach of this study may be novel, there is existing literature on the effects of vasopressors on uterine contractility, indicating potential for meaningful insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients who have given consent to participate in the study * Patients with gestational age 37-41 weeks * Patients previously diagnosed with either Type II or Gestational diabetes. For the healthy control group, no previous diagnosis is required for inclusion * Patients of 19-45 years * Patients of normal BMI (18-30 BMI) for the healthy control group only * Baby is registered as normal weight for size for the healthy control group only * Non-laboring patients, not exposed to exogenous oxytocin * Patients requiring elective primary or first repeat caesarean delivery * Patients undergoing caesarean delivery under spinal anesthesia Exclusion Criteria: * Patients who refuse to give written informed consent * Patients who require general anesthesia * Patients in labor and those receiving oxytocin for induction of labor * Emergency caesarean delivery in labor * Patients who have had previous uterine surgery involving myometrial dissection or \>1 previous caesarean delivery * Patients with risk factors for PPH such as those with polyhydramnios, preeclampsia, multiple gestation, morbid obesity, macrosomia (large for size baby), and previous history of PPH. However, for diabetic group, those with morbid obesity and macrosomia will not be excluded as these conditions are almost always associated with diabetes. * For the healthy control group only, a BMI \>30 or \<18 * Maternal age \>45
Where it's running
-
Mount Sinai Hospital
Toronto, Ontario, Canada Recruiting
Study contacts
- Principal investigator: Mrinalini Balki, MD — Mount Sinai Hospital
- Study coordinator: Mrinalini Balki, MD
- Email: mrinalini.balki@uhn.ca
- Phone: 416-586-4800
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Long-term outcomes after vacuum-induced tamponade for postpartum hemorrhage
This study will look at women who had postpartum hemorrhage treated with vacuum-induced tamponade at a Zurich hospital to see how they fared over time, including future pregnancies and fertility.
-
Calcium Gluconate After Birth to Reduce Blood Loss in Vaginal Delivery
This study tests whether giving calcium gluconate right after the baby is born can help reduce blood loss for people having a vaginal delivery.
-
Carbetocin Alone vs Carbetocin Plus Oxytocin After Elective Cesarean Delivery
This study tests whether giving carbetocin by itself after an elective cesarean is just as good as adding a supplemental oxytocin infusion.
-
Simulation-based postpartum hemorrhage training to boost anesthesiology team performance
Senior anesthesiology residents will try a high-fidelity simulation program for postpartum hemorrhage to see if it improves how their teams perform during obstetric emergencies.
-
Carbetocin to prevent heavy bleeding after twin birth
This trial tests whether a single dose of carbetocin given after the second twin is born reduces heavy bleeding compared with standard oxytocin in people delivering twins.
-
Draining the umbilical cord after birth to lower postpartum bleeding
This trial tests whether draining blood from the cut umbilical cord right after birth lowers heavy bleeding after delivery in women having a term vaginal birth.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.